ES2173943T3 - Sulfonas activas de polietilenglicol solubles en agua. - Google Patents

Sulfonas activas de polietilenglicol solubles en agua.

Info

Publication number
ES2173943T3
ES2173943T3 ES95901226T ES95901226T ES2173943T3 ES 2173943 T3 ES2173943 T3 ES 2173943T3 ES 95901226 T ES95901226 T ES 95901226T ES 95901226 T ES95901226 T ES 95901226T ES 2173943 T3 ES2173943 T3 ES 2173943T3
Authority
ES
Spain
Prior art keywords
active
peg
substances
polyethylenglycol
sulphones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95901226T
Other languages
English (en)
Inventor
J Milton Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics AL Corp
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater Corp filed Critical Shearwater Corp
Application granted granted Critical
Publication of ES2173943T3 publication Critical patent/ES2173943T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/326—Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

SE PRESENTA UN DERIVADO DE POLI(ETILENGLICOL) QUE SE ACTIVA CON UNA UNIDAD DE SULFONA PARA QUE SE ACOPLE DE FORMA SELECTIVA A LAS UNIDADES DE TIOL QUE HAY SOBRE LAS MOLECULAS Y SOBRE LAS SUPERFICIES. EL PEG ACTIVADO ES SOLUBLE EN AGUA, HIDROLITICAMENTE ESTABLE DURANTE MAYORES PERIODOS DE TIEMPO Y FORMA ENLACES HIDROLITICAMENTE ESTABLES CON LAS UNIDADES DE TIOL. LOS ENLACES SON GENERALMENTE IRREVERSIBLES EN ENTORNOS REDUCTORES. EL DERIVADO DE PEG ES UTIL PARA MODIFICAR LAS CARACTERISTICAS DE SUSTANCIAS INCLUIDA LA MODIFICACION DE MOLECULAS Y SUPERFICIES BIOLOGICAMENTE ACTIVAS PARA HACERLAS BIOCOMPATIBLES. TAMBIEN SE PRESENTAN METODOS PARA SINTETIZAR EL PEG ACTIVO Y PARA LA PREPARACION DE CONJUGADOS DEL PEG ACTIVO Y DE OTRAS SUSTANCIAS, INCLUIDAS LAS SUSTANCIAS BIOLOGICAMENTE ACTIVAS.
ES95901226T 1993-11-12 1994-11-14 Sulfonas activas de polietilenglicol solubles en agua. Expired - Lifetime ES2173943T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/151,481 US5446090A (en) 1993-11-12 1993-11-12 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Publications (1)

Publication Number Publication Date
ES2173943T3 true ES2173943T3 (es) 2002-11-01

Family

ID=22538958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95901226T Expired - Lifetime ES2173943T3 (es) 1993-11-12 1994-11-14 Sulfonas activas de polietilenglicol solubles en agua.

Country Status (26)

Country Link
US (6) US5446090A (es)
EP (2) EP0728155B1 (es)
JP (1) JP3114998B2 (es)
KR (1) KR100225746B1 (es)
CN (1) CN1085689C (es)
AT (1) ATE215577T1 (es)
AU (1) AU687937B2 (es)
BG (1) BG63399B1 (es)
BR (1) BR9408048A (es)
CA (1) CA2176203C (es)
CZ (1) CZ295640B6 (es)
DE (1) DE69430317T2 (es)
DK (1) DK0728155T3 (es)
EE (1) EE03448B1 (es)
ES (1) ES2173943T3 (es)
FI (1) FI117441B (es)
HK (1) HK1042312A1 (es)
HU (1) HU225649B1 (es)
NO (1) NO315377B1 (es)
NZ (1) NZ276313A (es)
PL (1) PL180149B1 (es)
RO (2) RO118434B1 (es)
RU (1) RU2176253C2 (es)
SK (1) SK284527B6 (es)
UA (1) UA58481C2 (es)
WO (1) WO1995013312A1 (es)

Families Citing this family (441)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU724960C (en) 1996-02-09 2002-08-15 Swedish Orphan Biovitrum Ab (Publ) Composition comprising interleukin-1 inhibitor and controlled release polymer
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
WO1998012274A1 (en) * 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
EP0946198B1 (en) * 1996-10-15 2002-06-19 Medical Analysis Systems, Inc. Method of stabilizing troponin I (cTnI) via conjugation with an active polymer
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
US6743248B2 (en) 1996-12-18 2004-06-01 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
US20030191496A1 (en) * 1997-03-12 2003-10-09 Neomend, Inc. Vascular sealing device with microwave antenna
US20040176801A1 (en) * 1997-03-12 2004-09-09 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
WO1998051336A1 (en) * 1997-05-15 1998-11-19 Theratech, Inc. Targeted delivery to t lymphocytes
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
WO1999011202A1 (en) * 1997-09-05 1999-03-11 Icet, Inc. Biomimetic calcium phosphate implant coatings and methods for making the same
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
CA2325568A1 (en) 1998-03-26 1999-09-30 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6458147B1 (en) 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
ATE364654T1 (de) * 1998-08-28 2007-07-15 Amylin Pharmaceuticals Inc Polyamideketten von genauer länge und deren konjugate mit proteinen
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
JP2002526430A (ja) 1998-09-22 2002-08-20 ザ、プロクター、エンド、ギャンブル、カンパニー 水不溶性基材と結合した活性タンパク質を含有するパーソナルケア組成物
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6830756B2 (en) 1998-11-06 2004-12-14 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en) 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US6949114B2 (en) 1998-11-06 2005-09-27 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2000033764A1 (en) * 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7744912B1 (en) 1999-02-01 2010-06-29 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2000078285A1 (en) * 1999-06-18 2000-12-28 University Of Medicine And Dentistry Of New Jersey Controlled release of therapeutics by in-situ entrapment by matrix cross-linking
JP2003505070A (ja) 1999-07-22 2003-02-12 ザ、プロクター、エンド、ギャンブル、カンパニー 定められたエピトープ領域においてアミノ酸置換を有するサブチリシンプロテアーゼ変異体
AU5928100A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
EP1196548A2 (en) 1999-07-22 2002-04-17 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US7008635B1 (en) * 1999-09-10 2006-03-07 Genzyme Corporation Hydrogels for orthopedic repair
US6303119B1 (en) 1999-09-22 2001-10-16 The Procter & Gamble Company Personal care compositions containing subtilisin enzymes bound to water insoluble substrates
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7074878B1 (en) * 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
DE60124699T2 (de) 2000-05-15 2007-09-13 Tecan Trading Ag Zweirichtungs-durchfluss-zentrifugalmikrofluid-vorrichtungen
DE60129432T2 (de) * 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CN1441808A (zh) * 2000-07-12 2003-09-10 格莱风治疗公司 趋化因子受体调制剂,制备和用途
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1315513B1 (en) * 2000-09-08 2011-03-09 Amylin Pharmaceuticals, Inc. "pseudo"-native chemical ligation
US7132475B2 (en) * 2000-10-19 2006-11-07 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems
EP1353701B1 (en) 2000-10-31 2011-12-21 PR Pharmaceuticals, Inc. Methods for producing compositions for enhanced delivery of bioactive molecules
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
CZ20032526A3 (cs) 2001-02-27 2003-12-17 Maxygen Aps Nové molekuly podobné interferonu beta
EP1379133A2 (en) * 2001-03-20 2004-01-14 Eidgenössische Technische Hochschule Zürich Two-phase processing of thermosensitive polymers for use as biomaterials
US6538104B2 (en) 2001-04-27 2003-03-25 Medical Analysis Systems, Inc. Stabilization of cardiac troponin I subunits and complexes
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
CA2457876C (en) * 2001-08-22 2011-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305313B1 (en) 2001-10-10 2014-03-26 ratiopharm GmbH Remodelling and glycoconjugation of interferon-alpha (IFNa)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
KR101009309B1 (ko) 2001-10-18 2011-01-18 넥타르 테라퓨틱스 아편양 길항제의 중합체 공액
EP1451356A1 (en) * 2001-11-23 2004-09-01 Simon Fredriksson Method and kit for proximity probing with multivalent proximity probes
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
US20030179692A1 (en) * 2002-03-19 2003-09-25 Yoshitaka Ohotomo Storage medium
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
AU2003243394B2 (en) 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
EP1517710B1 (en) 2002-06-21 2011-03-30 Novo Nordisk Health Care AG Pegylated factor vii glycoforms
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
CA2497777A1 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
KR20050083678A (ko) * 2002-09-05 2005-08-26 더 제너럴 하스피탈 코포레이션 아시알로-인터페론과 간암의 치료
ES2315526T3 (es) 2002-09-09 2009-04-01 Nektar Therapeutics Al, Corporation Metodo para preparar derivados polimericos solubles en agua que llevan un acido carboxilico terminal.
CN1312279C (zh) * 2002-11-07 2007-04-25 连云港新阳医药有限公司 聚乙二醇修饰门冬酰胺酶的制备方法
EA013535B1 (ru) * 2002-12-26 2010-06-30 Маунтин Вью Фамэсьютикэлс, Инк. Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
PT1667708E (pt) * 2002-12-26 2012-09-14 Mountain View Pharmaceuticals Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
MXPA05007348A (es) * 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CN1723232B (zh) * 2003-01-06 2012-08-22 尼克塔治疗公司 巯基选择性水溶性聚合物衍生物
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ATE448323T1 (de) * 2003-03-05 2009-11-15 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP1610825A2 (en) * 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
ATE540055T1 (de) 2003-05-09 2012-01-15 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2341960T3 (es) * 2003-07-22 2010-06-30 Nektar Therapeutics Procedimientos para preparar polimeros funcionalizados a partir de alcoholes polimericos.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1663281B1 (en) * 2003-08-29 2013-12-25 Dyax Corp. Poly-pegylated protease inhibitors
PT1675622T (pt) 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
MXPA06005732A (es) * 2003-11-24 2006-08-17 Neose Technologies Inc Eritropoyetina glucopegilada.
CA2548179A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2005206796B2 (en) * 2004-01-08 2011-06-16 Ratiopharm Gmbh O-linked glycosylation of peptides
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
KR100580644B1 (ko) * 2004-02-16 2006-05-16 삼성전자주식회사 생물분자를 고체 기판상에 비공유적으로 고정화 하는 방법및 그에 의하여 제조되는 마이크로어레이
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
EP1725262B1 (en) * 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
JP2007531715A (ja) * 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006047419A2 (en) * 2004-10-25 2006-05-04 Intezyne Technologies, Incorporated Heterobifunctional poly(ethylene glycol) and uses thereof
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
DE602005025805D1 (de) 2004-12-21 2011-02-17 Nektar Therapeutics San Carlos Stabilisierte polymer-thiol-reagenzien
CN102732588B (zh) * 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
SG161209A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
US9707252B2 (en) * 2005-02-09 2017-07-18 Covidien Lp Synthetic sealants
CA2602654A1 (en) 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
SI1881850T1 (sl) 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US9505867B2 (en) * 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
EP1926768B1 (en) 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007021297A1 (en) * 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
JP2009520949A (ja) * 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
US8293869B2 (en) * 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
US7743730B2 (en) * 2005-12-21 2010-06-29 Lam Research Corporation Apparatus for an optimized plasma chamber grounded electrode assembly
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
CN101420984B (zh) 2006-02-21 2013-01-02 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
WO2007127473A2 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
JP2009537609A (ja) 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
US8242179B2 (en) * 2006-06-23 2012-08-14 Surmodics, Inc. Hydrogel-based joint repair system and method
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
US8298801B2 (en) * 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US20080280818A1 (en) * 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2662755C (en) * 2006-09-08 2017-04-04 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
ES2457527T3 (es) * 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
BRPI0717505B8 (pt) * 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101583380B (zh) 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
EP2117603A2 (en) * 2006-12-19 2009-11-18 Bracco International B.V. Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
US8685417B2 (en) 2006-12-20 2014-04-01 Arkema, Inc. Polymer encapsulation and/or binding
JP5307030B2 (ja) 2007-01-18 2013-10-02 イーライ リリー アンド カンパニー ＰＥＧ化ＡβＦＡＢ
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008125655A1 (en) * 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
WO2008137471A2 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR20100046185A (ko) * 2007-08-09 2010-05-06 다이이찌 산쿄 가부시키가이샤 데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
AU2008289005A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2200932A4 (en) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2702043A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
MX2010004400A (es) 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
CA2706700A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US20090123519A1 (en) * 2007-11-12 2009-05-14 Surmodics, Inc. Swellable hydrogel matrix and methods
EP2209834B1 (en) * 2007-11-12 2011-06-08 Intradigm Corporation Heterobifunctional polyethylene glycol reagents
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20090226531A1 (en) * 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
PT2268635E (pt) 2008-04-21 2015-10-06 Taigen Biotechnology Co Ltd Compostos heterocíclicos
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US20110135623A1 (en) * 2008-05-16 2011-06-09 Nektar Therapeutics Conjugates of a Cholinesterase Moiety and a Polymer
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JP5622117B2 (ja) * 2008-07-21 2014-11-12 ポリテリクスリミテッド 生体分子を接合するための新規な試薬及び方法
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2737040C (en) * 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010033218A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
US20110171161A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
WO2010033227A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110171163A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of ziconotide peptides
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
EP2334334A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
JP5814793B2 (ja) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） ブロックコポリマーおよびその使用
RS58728B1 (sr) 2008-12-09 2019-06-28 Halozyme Inc Produženi rastvorljivi ph20 polipeptidi i njihove upotrebe
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
EP2396070A4 (en) 2009-02-12 2012-09-19 Incept Llc ACTIVE COMPOSITION WITH HYDROGEL PLUGS
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
PL2440239T3 (pl) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozycje hemoglobiny
RU2012107812A (ru) 2009-08-05 2013-09-10 Аллерган, Инк. Препараты мутеинов липокалинов с контролируемым высвобождением
EP2477603B1 (en) 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US9315860B2 (en) 2009-10-26 2016-04-19 Genovoxx Gmbh Conjugates of nucleotides and method for the application thereof
JP2013509422A (ja) 2009-10-30 2013-03-14 シーエヌエス セラピューティクス，インク． 改良されたニュールツリン分子
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
RS57870B1 (sr) 2010-01-06 2018-12-31 Dyax Corp Proteini koji vezuju kalikrein plazme
CN102161754B (zh) * 2010-02-13 2012-06-13 华中科技大学同济医学院附属协和医院 枝化状聚乙二醇衍生物的功能化修饰方法
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
CN103118692A (zh) 2010-04-26 2013-05-22 Atyr医药公司 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118693B (zh) 2010-04-29 2017-05-03 Atyr 医药公司 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2566495B1 (en) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
JP6396656B2 (ja) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CN103118695B (zh) 2010-07-12 2016-08-03 Atyr医药公司 与甘氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
KR102104222B1 (ko) 2010-07-30 2020-04-24 알콘 인코포레이티드 수분이 풍부한 표면을 갖는 실리콘 히드로겔 렌즈
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US10822374B2 (en) 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
KR102349549B1 (ko) 2010-11-12 2022-01-11 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
BR112013012858B1 (pt) 2010-11-24 2021-12-07 Lexicon Pharmaceuticals, Inc Anticorpo monoclonal que se liga a pectinacetilesterase de notum, composição farmacêutica, molécula de ácido nucleico, célula hospedeira e método para produzir o dito anticorpo
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
WO2012171335A1 (en) 2011-06-16 2012-12-20 The Hong Kong University Of Science And Technology Multi-vinylsulfone containing molecule
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
EA033472B1 (ru) 2011-06-17 2019-10-31 Halozyme Inc Композиция для стабилизации гиалуронидазы и ее применение
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
PL2717917T3 (pl) 2011-07-05 2016-12-30 Koniugaty p97 - przeciwciało
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
WO2013075117A2 (en) 2011-11-17 2013-05-23 John Wahren Pegylated c-peptide
CA2858161C (en) 2011-12-05 2020-03-10 Incept, Llc Medical organogel processes and compositions
AU2012362121B2 (en) 2011-12-29 2017-08-03 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
RU2659423C2 (ru) 2012-02-16 2018-07-02 ЭйТИР ФАРМА, ИНК. ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
BR112014024291B1 (pt) 2012-03-30 2022-07-05 The Board Of Regents Of The University Of Oklahoma Método para a produção de forma recombinante de um polímero de heparosan com alto peso molecular, uso do referido polímero para aumento de tecido, polinucleotídeo isolado e composição de material biológico compreendendo o referido polímero
WO2013151991A1 (en) 2012-04-02 2013-10-10 Surmodics, Inc. Hydrophilic polymeric coatings for medical articles with visualization moiety
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN104583235B (zh) 2012-06-08 2019-03-01 苏特罗生物制药公司 含位点特异非天然氨基酸残基的抗体、其制备和使用方法
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CA2906572A1 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
US10106590B2 (en) 2013-03-15 2018-10-23 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
JP2017505922A (ja) 2013-11-15 2017-02-23 タンジブル サイエンス リミテッド ライアビリティ カンパニー 親水性層を有するコンタクトレンズ
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CA2948864C (en) 2014-05-14 2023-10-17 Karl E. Griswold Deimmunized lysostaphin and methods of use
EP3674314B8 (en) 2014-06-10 2023-07-12 Amgen Inc. Apelin polypeptides
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
JP2017529331A (ja) 2014-08-22 2017-10-05 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｘｃｒ３に結合する抗原結合タンパク質
TR201907471T4 (tr) 2014-08-28 2019-06-21 Halozyme Inc Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
JP2017534612A (ja) 2014-10-14 2017-11-24 ポリセリックス・リミテッド Ｐｅｇの部分を含めた脱離基を含む試薬を用いるペプチド又はタンパク質のコンジュゲーションのための方法
TW202124419A (zh) 2014-10-24 2021-07-01 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3229851A4 (en) 2014-12-09 2018-08-01 Tangible Science LLC Medical device coating with a biocompatible layer
CA2979999A1 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
MX2017016251A (es) 2015-07-02 2018-04-20 Dana Farber Cancer Inst Inc Peptidos anti-microbianos estabilizados.
WO2017040329A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
SG11201806496SA (en) 2016-01-29 2018-08-30 Heyue Zhou Antigen binding proteins that bind pd-l1
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
US10421785B2 (en) 2016-04-11 2019-09-24 Bar-Ilan University Delta receptor agonist peptides and use thereof
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
AU2017315447B2 (en) 2016-08-26 2023-04-27 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
WO2018172503A2 (en) 2017-03-24 2018-09-27 Basf Se Liquid laundry detergent comprising modified saccharide or polysaccharide
WO2018213341A1 (en) 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
JP7091373B2 (ja) 2017-06-22 2022-06-27 カタリスト・バイオサイエンシーズ・インコーポレイテッド 改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
US11325955B2 (en) 2017-07-19 2022-05-10 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11897917B2 (en) 2017-09-27 2024-02-13 The University Of York Bioconjugation of polypeptides
AU2018383633B2 (en) 2017-12-15 2024-05-16 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
EP3732254A4 (en) 2017-12-26 2021-12-22 Becton, Dickinson and Company DEEP UV-EXCITABLE WATER-SOLVATIZED POLYMER DYES
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2019178313A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
EP3775052B1 (en) 2018-03-30 2024-06-05 Becton, Dickinson and Company Water-soluble polymeric dyes having pendant chromophores
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
AU2019327456A1 (en) 2018-08-28 2021-04-15 Ambrx, Inc. anti-CD3 antibody folate bioconjugates and their uses
AU2019337610A1 (en) 2018-09-11 2021-05-06 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2020131871A1 (en) * 2018-12-19 2020-06-25 Tangible Science, Inc. Systems and methods of treating a hydrogel-coated medical device
BR112021012601A2 (pt) 2018-12-28 2021-11-30 Catalyst Biosciences Inc Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
MX2021009644A (es) 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
US20220169688A1 (en) 2019-04-18 2022-06-02 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
EP3958983A1 (en) 2019-04-26 2022-03-02 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials
EP4077361A1 (en) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
CA3162922A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4114431A2 (en) 2020-03-04 2023-01-11 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
EP4139360A1 (en) 2020-04-22 2023-03-01 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
AU2021262752A1 (en) 2020-04-27 2022-10-13 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and HDMX-selective p53 peptides and uses thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
CA3193261A1 (en) 2020-10-14 2022-04-21 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
US20240002450A1 (en) 2020-11-05 2024-01-04 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
CA3231587A1 (en) 2021-09-08 2023-03-16 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784524A (en) * 1971-06-25 1974-01-08 Grace W R & Co Urethane/thioether-containing polyene composition and the reaction product thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4134887A (en) * 1973-10-17 1979-01-16 Hoechst Aktiengesellschaft Phenyl-azo-phenyl dyestuffs
CH586739A5 (es) * 1973-10-17 1977-04-15 Hoechst Ag
US4179387A (en) * 1974-03-12 1979-12-18 Fuji Photo Film Co., Ltd. Process for producing magnetic FE oxide
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2607766C3 (de) * 1976-02-26 1978-12-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung von trägergebundenen biologisch aktiven Substanzen
US4228019A (en) * 1978-06-19 1980-10-14 Texaco Development Corp. Secondary recovery process
US4473693A (en) * 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4296097A (en) * 1979-02-27 1981-10-20 Lee Weng Y Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor
US4430260A (en) * 1979-02-27 1984-02-07 Lee Weng Y Penicillin-polyvinyl alcohol conjugate and process of preparation
US4241199A (en) * 1979-09-18 1980-12-23 Union Carbide Corporation Novel polyester diols
US4280979A (en) * 1979-09-18 1981-07-28 Union Carbide Corporation Copolymers, compositions, and articles, and methods for making same
JPS585320A (ja) * 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
US4973493A (en) * 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
JPS59204144A (ja) * 1983-04-12 1984-11-19 Daikin Ind Ltd 新規含フッ素化合物およびその製法
SE470099B (sv) * 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4616644A (en) * 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4883864A (en) * 1985-09-06 1989-11-28 Minnesota Mining And Manufacturing Company Modified collagen compound and method of preparation
US4983494A (en) * 1985-10-16 1991-01-08 Fuji Photo Film Co., Ltd. Image forming process including heating step
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4871785A (en) * 1986-08-13 1989-10-03 Michael Froix Clouding-resistant contact lens compositions
DE3628717A1 (de) * 1986-08-23 1988-02-25 Agfa Gevaert Ag Haertungsmittel fuer proteine, eine damit gehaertete bindemittelschicht und eine solche schicht enthaltendes fotografisches aufzeichnungsmaterial
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
DE3634525A1 (de) * 1986-10-10 1988-04-21 Miles Lab Testmittel und indikatoren zum nachweis von thiolgruppen und verfahren zu deren herstellung
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NL8800577A (nl) * 1988-03-08 1989-10-02 Stichting Tech Wetenschapp Werkwijze voor het aanbrengen van een bloedcompatibele bekleding op polyetherurethaanvormstukken.
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
GB8824592D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
JP3122460B2 (ja) * 1990-08-31 2001-01-09 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ 固相用途のためのポリエチレングリコール誘導体
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
SE467308B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Fast yta belagd med ett hydrofilt ytterskikt med kovalent bundna biopolymerer, saett att framstaella en saadan yta och ett konjugat daerfoer
ATE190629T1 (de) * 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
DK52791D0 (da) * 1991-03-22 1991-03-22 Kem En Tec As Adsorptionsmatricer
DK130991D0 (da) * 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
CA2112992C (en) * 1991-07-04 2002-06-11 Allan O. F. Lihme Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
EP0622394A1 (en) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use

Also Published As

Publication number Publication date
CZ137596A3 (en) 1996-10-16
NO961918L (no) 1996-07-12
JP3114998B2 (ja) 2000-12-04
US7214366B2 (en) 2007-05-08
US20040037801A1 (en) 2004-02-26
NO315377B1 (no) 2003-08-25
EP1176160A2 (en) 2002-01-30
SK284527B6 (sk) 2005-05-05
DE69430317D1 (de) 2002-05-08
CN1085689C (zh) 2002-05-29
EP1176160A3 (en) 2004-03-03
RU2176253C2 (ru) 2001-11-27
US20020150548A1 (en) 2002-10-17
NZ276313A (en) 1997-04-24
ATE215577T1 (de) 2002-04-15
BR9408048A (pt) 1996-12-24
US20050209416A1 (en) 2005-09-22
HUP9601253A2 (en) 2001-06-28
EP0728155A1 (en) 1996-08-28
FI962004A (fi) 1996-05-10
AU1054895A (en) 1995-05-29
NO961918D0 (no) 1996-05-10
US5446090A (en) 1995-08-29
UA58481C2 (uk) 2003-08-15
CN1137280A (zh) 1996-12-04
DK0728155T3 (da) 2002-07-29
HK1042312A1 (zh) 2002-08-09
FI962004A0 (fi) 1996-05-10
HU9601253D0 (en) 1996-07-29
DE69430317T2 (de) 2002-10-02
CA2176203C (en) 2003-06-10
FI117441B (fi) 2006-10-13
AU687937B2 (en) 1998-03-05
WO1995013312A1 (en) 1995-05-18
KR960705869A (ko) 1996-11-08
US6894025B2 (en) 2005-05-17
EP0728155B1 (en) 2002-04-03
RO118434B1 (ro) 2003-05-30
US5739208A (en) 1998-04-14
CZ295640B6 (cs) 2005-09-14
EE03448B1 (et) 2001-06-15
SK60896A3 (en) 1997-04-09
JPH09508926A (ja) 1997-09-09
BG100568A (bg) 1996-12-31
US6610281B2 (en) 2003-08-26
PL314298A1 (en) 1996-09-02
PL180149B1 (pl) 2000-12-29
US5900461A (en) 1999-05-04
HU225649B1 (en) 2007-05-29
EE9600128A (et) 1997-04-15
CA2176203A1 (en) 1995-05-18
RO121855B1 (ro) 2008-06-30
KR100225746B1 (ko) 1999-10-15
BG63399B1 (bg) 2001-12-29

Similar Documents

Publication Publication Date Title
ES2173943T3 (es) Sulfonas activas de polietilenglicol solubles en agua.
ATE318580T1 (de) Gelzusammensetzungen und verfahren
DK116691D0 (da) Polypeptid-polymerkonjugater, der er aktive i saarheling
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
DK1061900T4 (da) Dermale præparater
AR017780A1 (es) Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo.
ES2058503T5 (es) Formulaciones farmaceuticas para uso parenteral.
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
ES2149768T3 (es) Conjugados de agentes enlazantes de celulas derivados de cc-1065.
DK0382128T3 (da) Tværbundet Hydrogel og dennes anvendelse som sårbandage
DK0725628T3 (da) Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
DK0418339T3 (da) Præparat og fremgangsmåde til forebyggelse af sammenvoksninger mellem kropsvæv
ES2129082T3 (es) Espumas de gel de poliuretano hidrofilo, en especial para el tratamiento de heridas profundas, apositos basados en espumas de gel de poliuretano hidrofilo y procedimiento de obtencion.
MA22885A1 (fr) Nouveaux composes actifs.
ES2132162T3 (es) Composiciones farmaceuticas que incluyen un farmaco, una sustancia polimerica reticulada, un aceite y un agente tensioactivo.
IT1282686B1 (it) Composti in grado di ridurre la tossicita' da farmaci
NO20052505L (no) Ny bruk av dextran-sulfat
ES2192560T3 (es) Material viscoelastico sintetico para aplicaciones oftalmicas.
EA200200151A1 (ru) Сухая порошкообразная композиция
WO1995016435A3 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
RU94002511A (ru) Искусственный хрусталик глаза
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
NO884941D0 (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 728155

Country of ref document: ES